CD8A and neoplasm: CTX014, an anti-Jagged 1/2 mAb, was tested in solid tumor at the preclinical stage, and results showed that CTX014 treatment overcame tumor-induced T cell tolerance, increased the infiltration of reactivated CD8+ T cells into tumors, and enhanced the efficacy of T cell–based immunotherapy [17].